实施17α-羟孕酮己酸酯预防复发性早产:定义、障碍与后续步骤
美国每年有超过50万新生儿在37周前出生,有早产史的女性复发风险高。每周注射17α-羟孕酮己酸酯可降低复发性早产风险,推荐用于有自发性单胎早产史的单胎妊娠女性,最早从16周开始。本文定义了17α-羟孕酮己酸酯的人群覆盖率,并描述了获得完整疗程需经历的步骤及提高覆盖率的潜在解决方案。
要点
- 17α-羟孕酮己酸酯推荐用于有自发性单胎早产史的单胎妊娠女性,最早从16周开始每周注射。
- 人群覆盖率指符合条件(既往自发性单胎早产)的女性中实际接受干预的比例。
- 获得完整疗程需经历多个步骤:及早产检、识别合格、提供、接受并坚持每周用药。
核心结论
- 17α-羟孕酮己酸酯可降低复发性早产风险,推荐用于有自发性单胎早产史的单胎妊娠女性,最早从16周开始。
- 人群覆盖率是衡量公共卫生项目效果的常用指标,定义为符合条件女性中实际接受干预的比例。
- 获得完整疗程需经历一系列步骤,本文描述了这些步骤及提高覆盖率的潜在解决方案。
研究设计与样本
- 本文为综述,描述实施17α-羟孕酮己酸酯预防复发性早产的定義、障碍与后续步骤。
主要发现
- 美国每年有超过50万新生儿在37周前出生。
- 有早产史的女性复发风险高。
- 每周注射17α-羟孕酮己酸酯可降低复发性早产风险。
- 获得完整疗程需经历及早产检、识别合格、提供、接受并坚持每周用药等步骤。
关键数值与推荐
- 推荐从最早16周开始每周注射17α-羟孕酮己酸酯,用于有自发性单胎早产史的单胎妊娠女性。
- 人群覆盖率定义为符合条件(既往妊娠并发自发性单胎早产)的女性中实际接受干预的比例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Each year in the United States, more than 500,000 neonates are born before 37 weeks of gestation. Women who have experienced a previous preterm birth are at high risk of recurrence. A weekly prenatal injection of 17α-hydroxyprogesterone caproate decreases the risk of recurrent preterm birth and is recommended from as early as 16 weeks of gestation in women carrying singleton pregnancies who have a history of spontaneous singleton preterm birth. A commonly used metric for public health program effectiveness is population coverage of an intervention. In the case of 17α-hydroxyprogesterone caproate, population coverage can be defined as the proportion of women who are eligible for 17α-hydroxyprogesterone caproate (ie, previous pregnancy complicated by spontaneous singleton preterm birth) who actually receive the intervention. To receive a full course of 17α-hydroxyprogesterone caproate, women must negotiate a complex series of steps that includes presenting early for prenatal care, being identified as eligible for 17α-hydroxyprogesterone caproate, being offered 17α-hydroxyprogesterone caproate, accepting 17α-hydroxyprogesterone caproate, and adhering to the weekly 17α-hydroxyprogesterone caproate dose schedule. We describe this series of steps as well potential solutions to increase 17α-hydroxyprogesterone caproate coverage.
引用
- Stringer EM, Vladutiu CJ, Batra P, et al. Operationalizing 17α-Hydroxyprogesterone Caproate to Prevent Recurrent Preterm Birth: Definitions, Barriers, and Next Steps. Obstet Gynecol. 2016. PMID: 27824772. doi:10.1097/AOG.0000000000001738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。